270 related articles for article (PubMed ID: 17108144)
1. Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor.
Kraus S; Gioeli D; Vomastek T; Gordon V; Weber MJ
Cancer Res; 2006 Nov; 66(22):11047-54. PubMed ID: 17108144
[TBL] [Abstract][Full Text] [Related]
2. Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action.
Migliaccio A; Di Domenico M; Castoria G; Nanayakkara M; Lombardi M; de Falco A; Bilancio A; Varricchio L; Ciociola A; Auricchio F
Cancer Res; 2005 Nov; 65(22):10585-93. PubMed ID: 16288052
[TBL] [Abstract][Full Text] [Related]
3. Regulation of androgen receptor activity by tyrosine phosphorylation.
Guo Z; Dai B; Jiang T; Xu K; Xie Y; Kim O; Nesheiwat I; Kong X; Melamed J; Handratta VD; Njar VC; Brodie AM; Yu LR; Veenstra TD; Chen H; Qiu Y
Cancer Cell; 2006 Oct; 10(4):309-19. PubMed ID: 17045208
[TBL] [Abstract][Full Text] [Related]
4. RACK1: a novel substrate for the Src protein-tyrosine kinase.
Chang BY; Harte RA; Cartwright CA
Oncogene; 2002 Oct; 21(50):7619-29. PubMed ID: 12400005
[TBL] [Abstract][Full Text] [Related]
5. RACK1 regulates Src-mediated Sam68 and p190RhoGAP signaling.
Miller LD; Lee KC; Mochly-Rosen D; Cartwright CA
Oncogene; 2004 Jul; 23(33):5682-6. PubMed ID: 15184885
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK.
Lee LF; Louie MC; Desai SJ; Yang J; Chen HW; Evans CP; Kung HJ
Oncogene; 2004 Mar; 23(12):2197-205. PubMed ID: 14767470
[TBL] [Abstract][Full Text] [Related]
7. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
8. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
9. Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer.
Reddy GP; Barrack ER; Dou QP; Menon M; Pelley R; Sarkar FH; Sheng S
J Cell Biochem; 2006 Aug; 98(6):1408-23. PubMed ID: 16619263
[TBL] [Abstract][Full Text] [Related]
10. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines.
Paliouras M; Diamandis EP
Biol Chem; 2008 Jun; 389(6):773-80. PubMed ID: 18627304
[TBL] [Abstract][Full Text] [Related]
11. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
12. Dihydrotestosterone interacts with EGFR/MAPK signalling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells.
Mukherjee B; Mayer D
Int J Oncol; 2008 Sep; 33(3):623-9. PubMed ID: 18695894
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
14. Ras signaling in prostate cancer progression.
Weber MJ; Gioeli D
J Cell Biochem; 2004 Jan; 91(1):13-25. PubMed ID: 14689577
[TBL] [Abstract][Full Text] [Related]
15. Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications.
Desai SJ; Ma AH; Tepper CG; Chen HW; Kung HJ
Cancer Res; 2006 Nov; 66(21):10449-59. PubMed ID: 17079466
[TBL] [Abstract][Full Text] [Related]
16. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells.
Takayama K; Horie-Inoue K; Ikeda K; Urano T; Murakami K; Hayashizaki Y; Ouchi Y; Inoue S
Biochem Biophys Res Commun; 2008 Sep; 374(2):388-93. PubMed ID: 18640093
[TBL] [Abstract][Full Text] [Related]
17. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.
Craft N; Shostak Y; Carey M; Sawyers CL
Nat Med; 1999 Mar; 5(3):280-5. PubMed ID: 10086382
[TBL] [Abstract][Full Text] [Related]
18. Signal transduction in prostate cancer progression.
Gioeli D
Clin Sci (Lond); 2005 Apr; 108(4):293-308. PubMed ID: 15603554
[TBL] [Abstract][Full Text] [Related]
19. Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha.
Buchanan G; Ricciardelli C; Harris JM; Prescott J; Yu ZC; Jia L; Butler LM; Marshall VR; Scher HI; Gerald WL; Coetzee GA; Tilley WD
Cancer Res; 2007 Oct; 67(20):10087-96. PubMed ID: 17942943
[TBL] [Abstract][Full Text] [Related]
20. The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer.
Zhoul J; Hernandez G; Tu SW; Huang CL; Tseng CP; Hsieh JT
Cancer Res; 2005 Nov; 65(21):9906-13. PubMed ID: 16267015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
